Introducing nanochemoprevention as a novel approach for cancer control: Proof of principle with green tea polyphenol epigallocatechin-3-gallate

Cancer Research

Volumn 69, Issue 5, 2009, Pages 1712-1716

  Siddiqui, Imtiaz A ^a   Adhami, Vaqar M ^a   Bharali, Dhruba J ^b   Hafeez, Bilal B ^a   Asim, Mohammad ^a   Khwaja, Sabih I ^a   Ahmad, Nihal ^a   Cui, Huadong ^b   Mousa, Shaker A ^b   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EPIGALLOCATECHIN GALLATE; MACROGOL; NANOPARTICLE; POLYLACTIC ACID; ANTINEOPLASTIC AGENT; CATECHIN; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BIOLOGICAL ACTIVITY; CANCER CONTROL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOCHEMOPREVENTION; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TEA; ANIMAL; APOPTOSIS; CELL SURVIVAL; CHEMISTRY; CHICK EMBRYO; DRUG EFFECT; DRUG SCREENING; DRUG STABILITY; EXPERIMENTAL NEOPLASM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CATECHIN; CELL SURVIVAL; CHICK EMBRYO; DRUG STABILITY; HUMANS; MICE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 62449295289     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3978     Document Type: Article

References (20)

1. The global burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020, 1996, Murray CJL, Lopez AD, eds. Cambridge, MA: Harvard University Press on behalf of the World Health Organization and the World Bank.
2. Siddiqui IA, Afaq F, Adhami VM, Mukhtar H. Prevention of prostate cancer through custom tailoring of chemopreventive regimen. Chem. Biol Interact 2008;171:122-32
3. Nishiyama N. Nanomedicine: nanocarriers shape up for long life. Nat Nanotechnol 2007;2:203-204
4. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J CUn 2008;58:71-96.
5. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006;66:2500-2505
6. Stuart EC, Scandlyn MJ, Rosengren RJ. Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci 2006;79:2329-36
7. Saleem M, Adhami VM, Siddiqui IA, Mukhtar H. Tea beverage in chemoprevention of prostate cancer: a mini-review. Nutr Cancer 2003:47:13-23.
8. Gref R, Mlnamitake Y, Peracchla MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994;263: 1600-3.
9. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-760
10. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007;9: 257-288
11. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995;.16:215-33.
12. Siddiqui IA. Malik A, Adhami VM, et al. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008; 27:2055-2063
13. Adhami VM, Malik A, Zaman N, et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007;13:1611-19
14. Saleem M, Maddodi N, Abu Zaid M, et al. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin. Cancer Res 2008;14:2119-27
15. Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ. The proangiogenic action of thyroid hormone analogue GC-I is initiated at an integrin. J Cardiovasc Pharmacol 2005;46:356-360
16. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature 1999:398:381.
17. Daliani D. Development of angiogenesis inhibition as therapy for prostate cancer. Oncology (Huntingt) 2000; 14:21-3
18. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597
19. Balogh L, Nigavekar SS, Nair BM, et al. Significant effect of size on. the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomedlcine 2007;3:281-296
20. Zhang L, Gu FX, Chan. JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008:83:761-769